The stock has corrected from the highs and is down nearly 19% in one month. Despite the correction, it is still up 385% in 2013. The merger with TransEnterix has boosted the stock's fortunes. The joining of Joseph Slattery is expected to help in development and commercialization of SurgiBot robotic system. He has relevant experience in medical technology companies. Dr. Frost's investment is one of the main reasons for investor interest in the prospects of the company. He has a significant stake in the company and has also joined the board. The merger is a significant event and future will be heavily dependent upon the synergies between the two companies. The merger is expected to help TransEnterix build upon its ability to bring flexible minimally invasive surgical technologies to market. Importantly, the funds raised by SafeStitch will help the combined entity develop its robotic system SurgiBot and other products. It has got access to the resources it requires to continue developing devices and to begin marketing them. SafeStitch had recently raised $30.2 million in a private placement. The TransEnterix investors contributed $19.7 million (65%) and Dr. Frost along with other investors, invested $10.5 million (35%). Such a significant investment by Dr. Frost indicates his faith in the prospects of TransEnterix. His investments in the pharmaceuticals / biotechnology sector are well known. His investment in Biozone (BZNE) has been in the news recently. Biozone owns the high potential proprietary drug delivery technology QuSomes. SafeStich has already appreciated significantly over the past few months, hence there is a possibility that the correction may run a bit deeper. Revenue benefits of the merger will take some time, so upward movements will be based more on expectations than fundamentals. On the other hand, the support of Dr. Frost cannot be underestimated. So there is always a possibility of resumption of the uptrend.